# Macrogenics Inc: financial statements, quarterly

MGNX · Nasdaq · CIK 1125345 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mgnx.md) · [Financials](/companies/mgnx/financials.md) · [Filings](/companies/mgnx/filings.md) · [Insiders](/companies/mgnx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mgnx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [10.4](/filings/0001125345-24-000160.md) | [10.7 d](/filings/0001125345-26-000017.md) | [9.1](/filings/0001125345-25-000053.md) | [10.8](/filings/0001125345-25-000101.md) | [111](/filings/0001125345-25-000108.md) | [19.4 d](/filings/0001125345-26-000017.md) | [13.2](/filings/0001125345-26-000038.md) | [6.9](/filings/0001125345-26-000056.md) | [72.8](/filings/0001125345-25-000108.md) | [41.2 d](/filings/0001125345-26-000017.md) | [20.8](/filings/0001125345-26-000038.md) | [32.8](/filings/0001125345-26-000056.md) |
| Cost of revenue | $m | [0.1](/filings/0001125345-24-000160.md) | [0.2 d](/filings/0001125345-26-000017.md) | [0.3](/filings/0001125345-25-000053.md) | [0.2](/filings/0001125345-25-000101.md) | [0.2](/filings/0001125345-25-000108.md) | [0.2 d](/filings/0001125345-26-000017.md) | [0.0](/filings/0001125345-25-000053.md) | [0.0](/filings/0001125345-25-000101.md) | [0.0](/filings/0001125345-25-000108.md) | [0.0 d](/filings/0001125345-26-000017.md) | not reported | not reported |
| Research and development | $m | [30.1](/filings/0001125345-24-000160.md) | [47.4 d](/filings/0001125345-26-000017.md) | [46.0](/filings/0001125345-25-000053.md) | [51.7](/filings/0001125345-25-000101.md) | [40.5](/filings/0001125345-25-000108.md) | [38.9 d](/filings/0001125345-26-000017.md) | [39.7](/filings/0001125345-26-000038.md) | [40.8](/filings/0001125345-26-000056.md) | [32.7](/filings/0001125345-25-000108.md) | [34.0 d](/filings/0001125345-26-000017.md) | [35.0](/filings/0001125345-26-000038.md) | [38.8](/filings/0001125345-26-000056.md) |
| Operating income | $m | [(35.5)](/filings/0001125345-24-000160.md) | [(49.4) d](/filings/0001125345-26-000017.md) | [(53.8)](/filings/0001125345-25-000053.md) | [(58.2)](/filings/0001125345-25-000101.md) | [54.2](/filings/0001125345-25-000108.md) | [(52.8) d](/filings/0001125345-26-000017.md) | [(42.6)](/filings/0001125345-26-000038.md) | [(43.2)](/filings/0001125345-26-000056.md) | [18.6](/filings/0001125345-25-000108.md) | [(12.1) d](/filings/0001125345-26-000017.md) | [(33.4)](/filings/0001125345-26-000038.md) | [(13.9)](/filings/0001125345-26-000056.md) |
| Interest expense | $m | [0.0](/filings/0001125345-24-000160.md) | [0.0 d](/filings/0001125345-25-000042.md) | [1.1](/filings/0001125345-25-000053.md) | [0.0](/filings/0001125345-25-000101.md) | [0.0](/filings/0001125345-25-000108.md) | [(0.0) d](/filings/0001125345-25-000042.md) | [0.1](/filings/0001125345-26-000038.md) | [0.8](/filings/0001125345-26-000056.md) | [3.3](/filings/0001125345-25-000108.md) | [4.3 d](/filings/0001125345-26-000017.md) | [4.9](/filings/0001125345-26-000038.md) | [4.4](/filings/0001125345-26-000056.md) |
| Income tax | $m | not reported | not reported | not reported | [0.0](/filings/0001125345-25-000101.md) | [0.0](/filings/0001125345-25-000108.md) | [0.9 d](/filings/0001125345-26-000017.md) | not reported | [0.1](/filings/0001125345-26-000056.md) | [0.0](/filings/0001125345-25-000108.md) | [(0.8) d](/filings/0001125345-26-000017.md) | not reported | [0.0](/filings/0001125345-26-000056.md) |
| Net income | $m | [17.6](/filings/0001125345-24-000160.md) | [(46.1) d](/filings/0001125345-26-000017.md) | [(52.2)](/filings/0001125345-25-000108.md) | [(55.7)](/filings/0001125345-25-000108.md) | [56.3](/filings/0001125345-25-000108.md) | [(15.4) d](/filings/0001125345-26-000017.md) | [(41.0)](/filings/0001125345-26-000056.md) | [(36.3)](/filings/0001125345-26-000056.md) | [16.8](/filings/0001125345-25-000108.md) | [(14.2) d](/filings/0001125345-26-000017.md) | [(36.8)](/filings/0001125345-26-000056.md) | [19.5](/filings/0001125345-26-000056.md) |
| Diluted EPS | $ per share | [0.28](/filings/0001125345-24-000160.md) | not reported | [(0.84)](/filings/0001125345-25-000053.md) | [(0.89)](/filings/0001125345-25-000101.md) | [0.90](/filings/0001125345-25-000108.md) | not reported | [(0.65)](/filings/0001125345-26-000038.md) | [(0.57)](/filings/0001125345-26-000056.md) | [0.27](/filings/0001125345-25-000108.md) | not reported | [(0.58)](/filings/0001125345-26-000038.md) | [0.31](/filings/0001125345-26-000056.md) |
| Basic EPS | $ per share | [0.28](/filings/0001125345-24-000160.md) | not reported | [(0.84)](/filings/0001125345-25-000053.md) | [(0.89)](/filings/0001125345-25-000101.md) | [0.90](/filings/0001125345-25-000108.md) | not reported | [(0.65)](/filings/0001125345-26-000038.md) | [(0.57)](/filings/0001125345-26-000056.md) | [0.27](/filings/0001125345-25-000108.md) | not reported | [(0.58)](/filings/0001125345-26-000038.md) | [0.31](/filings/0001125345-26-000056.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [89.9](/filings/0001125345-23-000124.md) | [101](/filings/0001125345-25-000042.md) | [80.4](/filings/0001125345-24-000088.md) | [83.9](/filings/0001125345-24-000148.md) | [180](/filings/0001125345-24-000160.md) | [183](/filings/0001125345-26-000017.md) | [146](/filings/0001125345-25-000053.md) | [131](/filings/0001125345-25-000101.md) | [80.1](/filings/0001125345-25-000108.md) | [57.2](/filings/0001125345-26-000056.md) | [66.5](/filings/0001125345-26-000038.md) | [114](/filings/0001125345-26-000056.md) |
| Current assets | $m | [291](/filings/0001125345-23-000124.md) | [251](/filings/0001125345-25-000042.md) | [203](/filings/0001125345-24-000088.md) | [157](/filings/0001125345-24-000148.md) | [222](/filings/0001125345-24-000160.md) | [217](/filings/0001125345-26-000017.md) | [182](/filings/0001125345-25-000053.md) | [205](/filings/0001125345-25-000101.md) | [232](/filings/0001125345-25-000108.md) | [220](/filings/0001125345-26-000056.md) | [183](/filings/0001125345-26-000038.md) | [322](/filings/0001125345-26-000056.md) |
| Total assets | $m | [340](/filings/0001125345-23-000124.md) | [298](/filings/0001125345-25-000042.md) | [248](/filings/0001125345-24-000088.md) | [201](/filings/0001125345-24-000148.md) | [264](/filings/0001125345-24-000160.md) | [262](/filings/0001125345-26-000017.md) | [225](/filings/0001125345-25-000053.md) | [245](/filings/0001125345-25-000101.md) | [271](/filings/0001125345-25-000108.md) | [257](/filings/0001125345-26-000056.md) | [218](/filings/0001125345-26-000038.md) | [345](/filings/0001125345-26-000056.md) |
| Current liabilities | $m | [51.3](/filings/0001125345-23-000124.md) | [56.1](/filings/0001125345-25-000042.md) | [55.8](/filings/0001125345-24-000088.md) | [57.9](/filings/0001125345-24-000148.md) | [59.3](/filings/0001125345-24-000160.md) | [55.5](/filings/0001125345-26-000017.md) | [55.4](/filings/0001125345-25-000053.md) | [39.0](/filings/0001125345-25-000101.md) | [44.5](/filings/0001125345-25-000108.md) | [43.1](/filings/0001125345-26-000056.md) | [95.9](/filings/0001125345-26-000038.md) | [109](/filings/0001125345-26-000056.md) |
| Total liabilities | $m | [146](/filings/0001125345-23-000124.md) | [146](/filings/0001125345-25-000042.md) | [142](/filings/0001125345-24-000088.md) | [143](/filings/0001125345-24-000148.md) | [144](/filings/0001125345-24-000160.md) | [146](/filings/0001125345-26-000017.md) | [145](/filings/0001125345-25-000053.md) | [199](/filings/0001125345-25-000101.md) | [204](/filings/0001125345-25-000108.md) | [201](/filings/0001125345-26-000056.md) | [197](/filings/0001125345-26-000038.md) | [303](/filings/0001125345-26-000056.md) |
| Shareholders' equity | $m | [194](/filings/0001125345-23-000124.md) | [153](/filings/0001125345-26-000017.md) | [106](/filings/0001125345-24-000088.md) | [57.8](/filings/0001125345-24-000148.md) | [120](/filings/0001125345-24-000160.md) | [116](/filings/0001125345-26-000017.md) | [79.1](/filings/0001125345-25-000053.md) | [46.6](/filings/0001125345-25-000101.md) | [67.0](/filings/0001125345-25-000108.md) | [55.6](/filings/0001125345-26-000056.md) | [21.2](/filings/0001125345-26-000038.md) | [42.9](/filings/0001125345-26-000056.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(35.2) d](/filings/0001125345-24-000160.md) | [(28.0) d](/filings/0001125345-26-000017.md) | [(45.6)](/filings/0001125345-25-000053.md) | [(44.5) d](/filings/0001125345-25-000101.md) | [60.2 d](/filings/0001125345-25-000108.md) | [(38.4) d](/filings/0001125345-26-000017.md) | [(46.9)](/filings/0001125345-26-000038.md) | [(47.0) d](/filings/0001125345-26-000056.md) | [(30.2) d](/filings/0001125345-25-000108.md) | [43.0 d](/filings/0001125345-26-000017.md) | [(35.8)](/filings/0001125345-26-000038.md) | [(40.7) d](/filings/0001125345-26-000056.md) |
| Capital expenditure | $m | [0.5 d](/filings/0001125345-24-000160.md) | [0.6 d](/filings/0001125345-26-000017.md) | [1.5](/filings/0001125345-25-000053.md) | [1.0 d](/filings/0001125345-25-000101.md) | [0.6 d](/filings/0001125345-25-000108.md) | [0.6 d](/filings/0001125345-26-000017.md) | [0.5](/filings/0001125345-26-000038.md) | [0.7 d](/filings/0001125345-26-000056.md) | [0.4 d](/filings/0001125345-25-000108.md) | [0.2 d](/filings/0001125345-26-000017.md) | [0.3](/filings/0001125345-26-000038.md) | [0.8 d](/filings/0001125345-26-000056.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [61.5](/filings/0001125345-23-000124.md) | [61.8](/filings/0001125345-24-000088.md) | [62.3](/filings/0001125345-24-000148.md) | [62.2](/filings/0001125345-24-000160.md) | [62.3](/filings/0001125345-25-000053.md) | [62.7](/filings/0001125345-25-000101.md) | [62.9](/filings/0001125345-25-000108.md) | [63.0](/filings/0001125345-26-000038.md) | [63.1](/filings/0001125345-26-000056.md) | [63.3](/filings/0001125345-25-000108.md) | [63.4](/filings/0001125345-26-000038.md) | [63.6](/filings/0001125345-26-000056.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 63,700,187 at 2026-08-08, from the cover of the [10-Q filed 2026-08-14](/filings/0001125345-26-000056.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.